| scholarly article | Q13442814 |
| P50 | author | John M. Kane | Q52274733 |
| Christoph Correll | Q56954221 | ||
| P2093 | author name string | Juan A Gallego | |
| Taishiro Kishimoto | |||
| Ladan Shaikh | |||
| Vladimir Olshanskiy | |||
| Jeffrey Nachbar | |||
| P2860 | cites work | Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics | Q24811190 |
| Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder | Q33301235 | ||
| Cost of antipsychotic polypharmacy in the treatment of schizophrenia | Q33327172 | ||
| Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service | Q33808059 | ||
| National trends in psychotropic medication polypharmacy in office-based psychiatry | Q34090959 | ||
| A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation | Q34298891 | ||
| Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. | Q34447495 | ||
| Schizophrenia, neuroleptic medication and mortality | Q34490208 | ||
| Past and Present Progress in the Pharmacologic Treatment of Schizophrenia | Q34726953 | ||
| Antipsychotic medication coprescribing in a large state hospital system | Q35077883 | ||
| Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients | Q35180801 | ||
| Clinicians' reasons for antipsychotic coprescribing. | Q36005087 | ||
| Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists | Q36054996 | ||
| Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature | Q37038719 | ||
| Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials | Q37137001 | ||
| Does the addition of a second antipsychotic drug improve clozapine treatment? | Q37147547 | ||
| Does antipsychotic polypharmacy increase the risk for metabolic syndrome? | Q37281587 | ||
| Polypharmacy with second-generation antipsychotics: a review of evidence | Q37341522 | ||
| Polypharmacy in schizophrenia | Q37669107 | ||
| Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. | Q37723434 | ||
| Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. | Q40474922 | ||
| Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? | Q41685984 | ||
| Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial | Q42162953 | ||
| Treatment with antipsychotics and the risk of diabetes in clinical practice | Q42872475 | ||
| Combination antipsychotics: pros, cons, and questions | Q44016011 | ||
| Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study | Q44022663 | ||
| Polypharmacy in patients with schizophrenia. | Q44662777 | ||
| 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia | Q45275037 | ||
| Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. | Q46087064 | ||
| How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs | Q46380111 | ||
| Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. | Q46679440 | ||
| Prescribing for inpatients with schizophrenia: an international multi-center comparative study | Q47707078 | ||
| Exploring regional variation in antipsychotic coprescribing practice: a Danish questionnaire survey. | Q50552283 | ||
| Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. | Q51942046 | ||
| Combination antipsychotic therapy in clinical practice. | Q51951314 | ||
| Augmentation With a Second Antipsychotic in Patients With Schizophrenia Who Partially Respond to Clozapine | Q57816406 | ||
| Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study | Q60621934 | ||
| Antipsychotic polypharmacy: squandering precious resources? | Q77716637 | ||
| Antipsychotic polypharmacy: evidence based or eminence based? | Q78336049 | ||
| Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment? | Q81347445 | ||
| P433 | issue | 1-3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 58-62 | |
| P577 | publication date | 2011-03-21 | |
| P1433 | published in | Schizophrenia Research | Q7431607 |
| P1476 | title | Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior | |
| P478 | volume | 131 |
| Q35795401 | A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona |
| Q92194258 | Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion? |
| Q36325431 | Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year Comparison |
| Q37609168 | Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis |
| Q50709810 | Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. |
| Q38081872 | Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness |
| Q37216848 | Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales |
| Q37029622 | Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice |
| Q33560808 | Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points |
| Q35948858 | Antipsychotic therapeutic drug monitoring: psychiatrists' attitudes and factors predicting likely future use. |
| Q64238772 | Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia |
| Q26800235 | Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice |
| Q48321579 | Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy. |
| Q50124634 | Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents |
| Q38020263 | Critical review of antipsychotic polypharmacy in the treatment of schizophrenia |
| Q30981989 | Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process |
| Q38138638 | History, background, concepts and current use of comedication and polypharmacy in psychiatry. |
| Q37042072 | Predictors of long-term (≥6months) antipsychotic polypharmacy prescribing in secondary mental healthcare |
| Q36057820 | Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. |
| Q38687957 | Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. |
| Q38769838 | Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials |
| Q36062421 | Safety and tolerability of antipsychotic polypharmacy |
| Q95597055 | The impact of a change in prescribing policy on antipsychotic prescribing in a general adult psychiatric hospital |
| Q47152270 | Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome |
Search more.